{"product_id":"zlab-bcg-matrix","title":"(ZLAB) Zai Lab Limited BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Zai Lab Limited BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZejula ovarian maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZejula is Zai Lab Limited’s flagship oncology brand in Greater China, and ovarian cancer maintenance stays a large, repeat-use market. The PARP inhibitor class is still expanding, so Zejula remains a Star in the BCG Matrix with strong growth potential. Its role in long-term maintenance after platinum response keeps demand durable and clinically relevant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQinlock GIST franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQinlock targets advanced GIST after prior kinase therapy, a rare niche with few direct substitutes, so it fits as a Star in Zai Lab Limited's BCG matrix. In INVICTUS, ripretinib cut median PFS to 6.3 months vs 1.0 month with placebo and delivered an 11.8% objective response rate. As physician use grows, the franchise still has room to expand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepotrectinib ROS1 TRK NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepotrectinib is a next-generation kinase inhibitor for biomarker-defined solid tumors, and ROS1-positive NSCLC is a small but expanding niche, at about 1%-2% of NSCLC cases. In 2025, that rare-disease profile still supports premium pricing and fast uptake where testing is available. If Zai Lab Limited executes launch well, the asset can scale quickly because unmet need is high and the target pool is clear.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOdronextamab B-cell lymphoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOdronextamab is a CD20xCD3 bispecific antibody in hematologic cancer, and bispecifics remain one of oncology’s fastest-growing classes. In B-cell lymphoma, this can fit a Stars profile if Zai Lab Limited can drive uptake fast; the global bispecific antibody market is still expanding at roughly 40%+ CAGR through 2030. \u003c\/p\u003e\n\u003cp\u003eIts value is tied to commercial execution, because CD20 is a validated lymphoma target and CD3 brings T-cell killing into play. If approved and scaled well, the program can turn into a high-growth revenue driver in lymphoma.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCD20xCD3 design supports rapid response\u003c\/li\u003e\n\u003cli\u003eBispecifics are growing fast in oncology\u003c\/li\u003e\n\u003cli\u003eBest case: strong lymphoma launch scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEfgartigimod autoimmune disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEfgartigimod is an FcRn-targeting biologic for autoimmune disease, and myasthenia gravis remains underdiagnosed in China, where prevalence is still low versus treated need. In Zai Lab Limited's portfolio, this looks like a Star because the franchise can scale fast in a market with limited biologic penetration and strong clinical demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFcRn inhibition targets pathogenic IgG.\u003c\/li\u003e\n\u003cli\u003eMG demand in China is still underpenetrated.\u003c\/li\u003e\n\u003cli\u003eClear blockbuster-style growth case.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZai Lab’s star drugs drive 2025-2026 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZai Lab Limited’s Stars are high-growth, high-need launches with clear scale potential in 2025-2026. Zejula stays the core driver in ovarian cancer, Qinlock has proven 6.3-month PFS in GIST, and repotrectinib addresses the 1%-2% ROS1-positive NSCLC niche. Odronextamab and efgartigimod add fast-growing hematology and autoimmune upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar case\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZejula\u003c\/td\u003e\n\u003ctd\u003eOvarian maintenance\u003c\/td\u003e\n\u003ctd\u003eRepeat-use market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQinlock\u003c\/td\u003e\n\u003ctd\u003eAdvanced GIST\u003c\/td\u003e\n\u003ctd\u003e6.3 mo PFS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepotrectinib\u003c\/td\u003e\n\u003ctd\u003eROS1 NSCLC\u003c\/td\u003e\n\u003ctd\u003e1%-2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eZai Lab’s BCG Matrix maps its pipeline and marketed drugs into invest, hold, or divest priorities amid biotech growth and competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG view of Zai Lab Limited to pinpoint cash cows, stars, and drag points fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists the key sources behind Zai Lab Limited’s analysis, making the data easier to verify, trust, and use in decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZejula recurrent ovarian base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZejula is Zai Lab Limited’s most mature revenue stream, with an established physician base and repeat use in ovarian cancer maintenance. Growth is slower than newer assets, but it still acts like a classic cash cow: high familiarity, low selling friction, and steadier replenishment from ongoing patient use. In Zai Lab Limited’s latest reported results, Zejula remained a core product, supporting recurring cash generation rather than breakout growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQinlock mature GIST sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQinlock is already commercial in China for late-line GIST, a rare cancer with only about 10 to 15 new cases per million people each year. That small, well-defined pool supports repeatable sales once doctors adopt it, so this looks more like a steady cash base than a heavy-growth launch. In BCG terms, mature niche demand can keep Qinlock generating cash with limited extra selling spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptune neuro-oncology base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOptune in glioblastoma fits a Cash Cow profile because it serves a narrow specialist market and is used through tumor-treatment centers, so sales tend to repeat once a center is onboarded. The franchise sits in a disease with about 15-month median survival under standard care, which keeps the need for ongoing, device-based therapy high but growth limited versus launch-stage assets.\u003c\/p\u003e\n\u003cp\u003eIts revenue base is steadier than trial-driven oncology launches because demand is tied to installed center use, patient eligibility, and refill cycles rather than one-time prescribing spikes. That makes Optune a more predictable contributor to Zai Lab Limited’s portfolio, even if the addressable glioblastoma pool is small.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNUZYRA hospital anti-infective base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNUZYRA is Zai Lab Limited's steady hospital anti-infective base, used in acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. It gives recurring demand because these infections keep coming back in inpatient and discharge care, even when growth is not fast. In 2025, its value is cash flow stability, not breakout scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 core hospital indications\u003c\/li\u003e\n\u003cli\u003eRecurring antibiotic demand\u003c\/li\u003e\n\u003cli\u003eCash flow over growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChina commercial platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZai Lab Limited's China commercial platform is a cash cow because it already has regulatory, medical, and sales coverage in Mainland China and Hong Kong, so each new launch adds far less cost. In 2025, that shared base supported more than one product launch and helped turn approved drugs into recurring revenue. The result is a mature asset that helps fund the pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower launch cost per new product\u003c\/li\u003e\n\u003cli\u003eExisting China and Hong Kong reach\u003c\/li\u003e\n\u003cli\u003eRecurring cash for R\u0026amp;D funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZai Lab’s 2025 Cash Cows: Steady R\u0026amp;D Fuel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Zai Lab Limiteds Cash Cows were Zejula, Qinlock, Optune, and NUZYRA: mature products with repeat use, niche demand, and low added selling spend. They are less about fast growth and more about steady, recurring cash for R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZejula\u003c\/td\u003e\n\u003ctd\u003eEstablished repeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQinlock\u003c\/td\u003e\n\u003ctd\u003eRare cancer niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNUZYRA\u003c\/td\u003e\n\u003ctd\u003eRecurring hospital demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eZai Lab Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Zai Lab Limited BCG Matrix report you’ll receive after purchase. The full document is the same final version—no demo content, no placeholders, and no watermarks. Once purchased, it’s ready for immediate download, use, or sharing with your team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargetuximab HER2 cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMargetuximab is a Dog for Zai Lab Limited: in HER2 breast and gastroesophageal cancers, it faces entrenched rivals like trastuzumab, pertuzumab, and HER2 ADCs such as Enhertu, which posted 2025 sales above $4 billion globally. The FDA label is limited to post-prior anti-HER2 therapy use, so the addressable pool is narrow. With Zai Lab 2025 total product revenue far more concentrated in core growth assets, margetuximab adds limited upside. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTebotelimab oncology program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTebotelimab is still a development-stage oncology asset, so it has 0 commercial sales and no scale yet. In Zai Lab Limited’s BCG Matrix, that fits a Dog profile today. To avoid low-return status, it needs strong Phase 2\/3 data and a clear path to approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZL-2309 CDC7 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZL-2309 is an internal, early-stage oncology asset, so it has no launched market and no revenue base today. In BCG terms, that makes it a Dog: low current cash contribution, while development still consumes R\u0026amp;D spend and management time. With revenue at US$0 for this program, it is capital intensive relative to proven cash generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZL-1201 antibody program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZL-1201 is still in discovery or early development, so it has no established market share and no disclosed 2025\/2026 revenue contribution for Zai Lab Limited. In BCG terms, it stays a Dogs asset until proof of concept and clinical data improve. That makes it a weak portfolio contributor right now.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage, no market share\u003c\/li\u003e\n\u003cli\u003eNo 2025\/2026 sales disclosed\u003c\/li\u003e\n\u003cli\u003eWeak BCG contributor today\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZL-2314 EGFR inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZL-2314 sits in Dogs: it targets EGFR mutation biology in a crowded NSCLC field where EGFR mutations appear in about 10% to 15% of Western and 40% to 50% of Asian lung cancers. With osimertinib already setting a high efficacy bar, Zai Lab Limited needs clear differentiation on response, safety, or resistance coverage or the program stays low-value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh competition\u003c\/li\u003e\n\u003cli\u003eWeak pricing power\u003c\/li\u003e\n\u003cli\u003eDifferentiation is key\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZai Lab’s Dog Assets Burn Cash, Deliver Little Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at Zai Lab Limited are low-share, low-return assets: margetuximab faces entrenched HER2 rivals, tebotelimab has no sales, and ZL-2309, ZL-1201, and ZL-2314 remain early-stage with no 2025\/2026 revenue. These programs consume R\u0026amp;D while adding little cash. In a crowded oncology market, weak differentiation keeps upside limited.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargetuximab\u003c\/td\u003e\n\u003ctd\u003eNarrow label\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTebotelimab\u003c\/td\u003e\n\u003ctd\u003e0 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZL-2309\u003c\/td\u003e\n\u003ctd\u003eEarly-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZL-1201\u003c\/td\u003e\n\u003ctd\u003eNo revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZL-2314\u003c\/td\u003e\n\u003ctd\u003eHigh competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdagrasib KRAS G12C\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdagrasib targets KRAS G12C solid tumors and already has U.S. approval in NSCLC and colorectal cancer, which supports fast demand in lung cancer, where KRAS mutations appear in about 13% of cases. For Zai Lab Limited, this looks like a Question Mark in China: the market is growing, but share stays unclear until local approval and launch execution land. The upside is real, but so is the regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBemarituzumab FGFR2b gastric\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBemarituzumab is aimed at FGFR2b-positive gastric and gastroesophageal cancers, a small but high-need segment with no clear standard targeted option. Zai Lab said the drug is still in late-stage development, so it has commercial upside, but it has not yet shown share or launch traction. That makes it a classic Question Mark: high potential, low proven sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLN-081 EGFR exon 20\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCLN-081 targets EGFR exon 20 insertion NSCLC, a small but clinically important group that makes up about 2% to 4% of EGFR-mutant NSCLC cases. In Zai Lab Limited’s BCG view, that puts it in Question Marks: high need, but a narrow pool and still uncertain uptake. If it wins share in this niche, especially in China where NSCLC is the top cancer and was about 1.06 million new cases in 2022, it could grow into a real asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eElzovantinib kinase inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElzovantinib is a multi-targeted kinase program, so it fits Zai Lab Limited's Question Marks: big scope, low proven share. Zai Lab Limited reported 2024 revenue of about $399 million, but Elzovantinib still has no disclosed commercial sales, so value depends on clinical wins, not current demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad oncology targets can widen future use\u003c\/li\u003e\n\u003cli\u003eCurrent market share is still unproven\u003c\/li\u003e\n\u003cli\u003eSuccess now depends on development and approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKarXT psychiatry neurology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKarXT targets schizophrenia and other neuropsychiatric disorders with very large treated pools; schizophrenia affects about 24 million people worldwide, and China is one of the biggest addressable markets. For Zai Lab Limited, the asset can move from a question mark to a star only if China development, reimbursement, and prescribing uptake all land well. Until local access is proven, the commercial upside stays promising but untested.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge patient pool, strong upside\u003c\/li\u003e\n\u003cli\u003eChina access is the key gate\u003c\/li\u003e\n\u003cli\u003eStill a question mark until uptake shows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZai Lab’s Question Marks Could Pay Off in China’s Biggest Drug Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdagrasib, bemarituzumab, CLN-081, elzovantinib, and KarXT are Question Marks for Zai Lab Limited because each targets a clear unmet need, but China share is still unproven. The upside is biggest where patient pools are large, like schizophrenia at 24 million people worldwide and NSCLC at 1.06 million new China cases in 2022.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdagrasib\u003c\/td\u003e\n\u003ctd\u003eApproval pending in China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBemarituzumab\u003c\/td\u003e\n\u003ctd\u003eLate-stage, no sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLN-081\u003c\/td\u003e\n\u003ctd\u003eNiche EGFR group\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKarXT\u003c\/td\u003e\n\u003ctd\u003eBig market, unproven uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235183042825,"sku":"zlab-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/zlab-bcg-matrix.webp?v=1785736915","url":"https:\/\/dcfanalyst.com\/products\/zlab-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}